Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStoptm for the treatment of acid reflux, a treatment field ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy for adult patients with unresectable or metastatic hormone receptor ...

The Munich-based company has confirmed that its prospective, randomised, open-label trial of ITM-11 met its primary endpoint demonstrating a statistically significant benefit in progression-free ...

Metsera is offering 17.2 million shares priced between $15 and $17 for its Nasdaq listing. Image credit: Shutterstock/ Tada Images. US-based Metsera has set its sights on a $289m public listing as the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Funding This study received funding from NeuroVasc Inc. Competing interests HI reports lecturer’s fees from Medtronic, Daiichi Sankyo, Terumo, Johnson & Johnson, Stryker, and Asahi Intec. TS reports a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Another day, another president. Good morning! Today, we hear from ...

However, the asset faced a series of setbacks in 2024. The FDA on Friday approved AstraZeneca and Daiichi Sankyo’s Dato-DXd, to be known as Datroway, for patients with certain advanced breast ...